Astragalin mitigates inflammatory osteolysis by negatively modulating osteoclastogenesis via ROS and MAPK signaling pathway.
Xing F, Geng L, Guan H, Liu D, Li Y, Zeng L, Chen Y, Tian R, Li Z, Cao R, Zhao Y, Yan P, Qiang H, Kong N, Wang K, Yang P.
Xing F, et al. Among authors: kong n.
Int Immunopharmacol. 2022 Nov;112:109278. doi: 10.1016/j.intimp.2022.109278. Epub 2022 Oct 7.
Int Immunopharmacol. 2022.
PMID: 36215870